EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+6.72%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.31B
AUM Growth
+$1.31B
(-2.3%)
Cap. Flow
-$14M
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
61.23%
Holding
86
New
16
Increased
25
Reduced
27
Closed
12
Top Buys
| 1 |
Insmed
INSM
|
$77.4M |
| 2 |
Repligen
RGEN
|
$23.5M |
| 3 |
Inspire Medical Systems
INSP
|
$15M |
| 4 |
Novo Nordisk
NVO
|
$12.1M |
| 5 |
HCA Healthcare
HCA
|
$10.2M |
Top Sells
| 1 |
Natera
NTRA
|
$65.5M |
| 2 |
Pfizer
PFE
|
$30.6M |
| 3 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$26.2M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$21.2M |
| 5 |
Tenet Healthcare
THC
|
$18.5M |
Sector Composition
| 1 | Healthcare | 99.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GSK
GSK
$79.9B
| $134M | 9.14% | 3,468,080 -303,914 | -8% | -$11.7M |
|
|
2
Natera
NTRA
$23.1B
| $127M | 8.7% | 1,173,494 -604,557 | -34% | -$65.5M |
|
|
3
Insmed
INSM
$28.8B
| $77.4M | 5.3% | +1,155,588 | New | +$77.4M |
|
|
4
Teva Pharmaceuticals
TEVA
$21.1B
| $76.7M | 5.25% | 4,720,460 -1,304,709 | -22% | -$21.2M |
|
5
United Therapeutics
UTHR
$13.8B
| $75M | 5.13% | 235,351 -15,784 | -6% | -$5.03M |
|
6
Syndax Pharmaceuticals
SNDX
$1.41B
| $74.2M | 5.08% | 3,613,631 +480,518 | +15% | +$9.87M |
|
7
Vera Therapeutics
VERA
$1.38B
| $73.9M | 5.06% | 2,043,214 +219,433 | +12% | +$7.94M |
|
|
8
Inspire Medical Systems
INSP
$2.77B
| $71.3M | 4.88% | 533,011 +112,312 | +27% | +$15M |
|
9
Revvity
RVTY
$10.5B
| $47.4M | 3.24% | 451,582 -31,578 | -7% | -$3.31M |
|
|
10
HCA Healthcare
HCA
$94.5B
| $43.5M | 2.98% | 135,480 +31,659 | +30% | +$10.2M |
|
11
Bio-Techne
TECH
$8.5B
| $38.9M | 2.66% | 543,044 -64,643 | -11% | -$4.63M |
|
12
HealthEquity
HQY
$7.72B
| $35.6M | 2.44% | 413,531 -7,814 | -2% | -$674K |
|
13
Community Health Systems
CYH
$387M
| $27M | 1.85% | 8,037,470 +56,829 | +0.7% | +$191K |
|
|
14
Repligen
RGEN
$6.88B
| $24.5M | 1.68% | 194,291 +186,054 | +2,259% | +$23.5M |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $23.4M | 1.6% | 633,015 -78,100 | -11% | -$2.89M |
|
16
Ionis Pharmaceuticals
IONS
$6.79B
| $21.8M | 1.49% | 456,881 +80,443 | +21% | +$3.83M |
|
|
17
Novo Nordisk
NVO
$251B
| $21M | 1.44% | 146,956 +84,612 | +136% | +$12.1M |
|
18
Eli Lilly
LLY
$657B
| $19.2M | 1.32% | 21,233 +8,356 | +65% | +$7.57M |
|
19
Protagonist Therapeutics
PTGX
$3.67B
| $17.5M | 1.2% | 505,836 +94,358 | +23% | +$3.27M |
|
20
argenx
ARGX
$43.6B
| $14.9M | 1.02% | 34,593 -19,925 | -37% | -$8.57M |
|
21
Humana
HUM
$36.5B
| $14.2M | 0.97% | 38,023 +2,491 | +7% | +$931K |
|
22
Viatris
VTRS
$12.3B
| $14.1M | 0.97% | 1,329,282 +12,813 | +1% | +$136K |
|
23
ZimVie
ZIMV
$532M
| $14M | 0.96% | 767,659 +203,161 | +36% | +$3.71M |
|
24
MannKind Corp
MNKD
$1.41B
| $11.8M | 0.81% | 2,256,952 -134,176 | -6% | -$700K |
|
25
Brookdale Senior Living
BKD
$1.83B
| $10.6M | 0.72% | 1,546,842 +228,077 | +17% | +$1.56M |
|